Jade Biosciences, Inc.
JBIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001798749
No open-market purchases or sales by Jade Biosciences, Inc. insiders were filed in the last 90 days; 153 institutions reported holding it in 13F filings for Q2 2026, worth $1.62B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Jade Biosciences, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Jade Biosciences, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Eisner Mark | Director | – | Jun 26, 2026 | 1 |
| Harwin Peter Evan | Director, 10% Owner | 1,897,677Indirect | Jun 11, 2026 | 2 |
| Fairmount Healthcare Fund II L.P. | Director, 10% Owner | 1,897,677Indirect | Jun 11, 2026 | 2 |
| Fairmount Funds Management LLC | Director, 10% Owner | 1,897,677Indirect | Jun 11, 2026 | 2 |
| Kiselak Tomas | Director, 10% Owner | 1,897,677Indirect | Jun 11, 2026 | 2 |
| Fairmount Healthcare Co-Invest IV L.P. | Director, 10% Owner | 1,897,677Indirect | Jun 11, 2026 | 2 |
| Dobmeier Eric | Director | – | Jun 11, 2026 | 1 |
| Lavelle Erin | Director | – | Jun 11, 2026 | 1 |
| Klein Lawrence Otto | Director | – | Jun 11, 2026 | 1 |
| Cain Christopher W. | Director | – | Jun 11, 2026 | 1 |
| Dahms Bradford D. | Chief Financial Officer | 37,813 | Feb 13, 2026 | 1 |
| King Andrew James | See Remarks | 386,113 | Feb 13, 2026 | 1 |
| Frohlich Tom | Chief Executive Officer | 86,331 | Feb 13, 2026 | 1 |
| Bekiroglu Elizabeth | See Remarks | 28,125 | Feb 13, 2026 | 1 |
| RA Capital Healthcare Fund LP | 10% Owner | 1,287,858Indirect | Apr 30, 2025 | 0 |
| Ra Capital Management, L.P. | 10% Owner | 1,287,858Indirect | Apr 30, 2025 | 0 |
| Kolchinsky Peter | 10% Owner | 1,287,858Indirect | Apr 30, 2025 | 0 |
| Shah Rajeev M. | 10% Owner | 1,287,858Indirect | Apr 30, 2025 | 0 |
| Dake Benjamin T | SEE REMARKS | 14,252 | Aug 2, 2024 | 0 |
| RA Capital Nexus Fund, L.P. | Director | 7,893,678Indirect | Jun 20, 2024 | 0 |
| Eldridge George A | SEE REMARKS | 5,022 | Jun 14, 2024 | 0 |
| Gillies Hunter | CHIEF MEDICAL OFFICER | 5,602 | Jun 14, 2024 | 0 |
| Verwijs Marinus | CHIEF TECHNICAL OFFICER | 0 | Jun 14, 2024 | 0 |
| Santel Donald J | Director | – | Jun 7, 2024 | 0 |
| Iwicki Mark T | Director | – | Jun 7, 2024 | 0 |
| Dorval Allison | Director | – | Jun 7, 2024 | 0 |
| Dable Habib J | Director | – | Jun 7, 2024 | 0 |
| Resnick Joshua | Director | – | Jun 7, 2024 | 0 |
| Katabi Maha | Director, 10% Owner | 3,758,686Indirect | Jun 7, 2024 | 0 |
| Grayzel David S. | Director | 14,502Indirect | Jun 7, 2024 | 0 |
| Noyes Timothy P | CHIEF EXECUTIVE OFFICER | 0 | May 17, 2024 | 0 |
| Niven Ralph | CHIEF SCIENTIFIC OFFICER | 1,609 | Feb 7, 2024 | 0 |
| Pigot Timothy | CHIEF COMMERCIAL OFFICER | – | Jan 24, 2024 | 0 |
| Atlas Venture Fund XII, L.P. | 10% Owner | 2,327,909 | Jul 19, 2022 | 0 |
| Cormorant Asset Management, LP | Other: Former 10% Owner | 2,030,691Indirect | Jul 7, 2021 | 0 |
| Chen Bihua | Other: Former 10% Owner | 2,030,691Indirect | Jul 7, 2021 | 0 |
| Cormorant Global Healthcare Master Fund, LP | Other: Former 10% Owner | 2,030,691Indirect | Jul 7, 2021 | 0 |
| Cormorant Private Healthcare Fund II, LP | Other: Former 10% Owner | 2,030,691Indirect | Jul 7, 2021 | 0 |
| Healy James | 10% Owner | 3,758,686 | Jul 6, 2021 | 0 |
| Sofinnova Management X, L.P. | 10% Owner | 3,758,686 | Jul 6, 2021 | 0 |
| Sofinnova Venture Partners X, L.P. | 10% Owner | 3,758,686 | Jul 6, 2021 | 0 |
| Atlas Venture Associates XII, LLC | 10% Owner | 3,103,879 | Jul 6, 2021 | 0 |
| Atlas Venture Associates XII, L.P. | 10% Owner | 3,103,879 | Jul 6, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 14, 2024 (view filing) | Jun 14 | Same day | Verwijs MarinusCHIEF TECHNICAL OFFICER | SSale | −10.6K | $25.00 | −$265.0K | −100.0%0 after | 10b5-1 |
| Jun 14, 2024 (view filing) | Jun 14 | Same day | Eldridge George ASEE REMARKS | SSale | −15.0K | $25.03 | −$375.4K | −74.9%5.02K after | 10b5-1 |
| Jun 20, 2024 (view filing)5:56 PM ET | Jun 17 | 3 days | RA Capital Healthcare Fund LP and 4 othersDirector, 10% Owner | PPurchase | +928.1K | $1.67 | +$1.55M | +13.3%7.89M after | |
| May 19, 2025 (view filing) | May 16 | 3 days | Frohlich TomChief Executive Officer | PPurchase | +6.00K | $7.40 | +$44.4K | New position6.00K after |